rs121918799
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 1P and 8B. PP2BP4_StrongBS2
The NM_001165963.4(SCN1A):āc.3521C>Gā(p.Thr1174Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00163 in 1,612,736 control chromosomes in the GnomAD database, including 11 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001165963.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN1A | NM_001165963.4 | c.3521C>G | p.Thr1174Ser | missense_variant | 20/29 | ENST00000674923.1 | NP_001159435.1 | |
LOC102724058 | NR_110598.1 | n.199G>C | non_coding_transcript_exon_variant | 2/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN1A | ENST00000674923.1 | c.3521C>G | p.Thr1174Ser | missense_variant | 20/29 | NM_001165963.4 | ENSP00000501589 | P4 | ||
SCN1A-AS1 | ENST00000651574.1 | n.216G>C | non_coding_transcript_exon_variant | 2/19 |
Frequencies
GnomAD3 genomes AF: 0.00148 AC: 224AN: 151852Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00165 AC: 415AN: 251166Hom.: 3 AF XY: 0.00177 AC XY: 240AN XY: 135746
GnomAD4 exome AF: 0.00165 AC: 2409AN: 1460766Hom.: 11 Cov.: 31 AF XY: 0.00169 AC XY: 1226AN XY: 726646
GnomAD4 genome AF: 0.00147 AC: 224AN: 151970Hom.: 0 Cov.: 32 AF XY: 0.00163 AC XY: 121AN XY: 74284
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | May 06, 2019 | This variant is associated with the following publications: (PMID: 24842605, 24679980, 22780858, 25576396, 24664660, 23801004, 23398611, 11254445, 22550089, 18021921, 21396429, 26990884, 27017028, 26763045, 26236192, 20301562, 31782251, 31765958) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 27, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | SCN1A: BP4, BS1, BS2 - |
Migraine, familial hemiplegic, 3 Uncertain:1Benign:1Other:1
not provided, no classification provided | literature only | UniProtKB/Swiss-Prot | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2016 | This variant was classified as: Uncertain significance. - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Oct 12, 2020 | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 05, 2022 | Variant summary: SCN1A c.3521C>G (p.Thr1174Ser) results in a conservative amino acid change located in the Sodium ion transport-associated domain (IPR010526) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0017 in 251678 control chromosomes (gnomAD, Escayg_2001, Yordanova_2011, Cestele_2013), predominantly at a frequency of 0.0027 within the Non-Finnish European subpopulation in the gnomAD database, including 3 homozygotes. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 150-fold of the estimated maximal expected allele frequency for a pathogenic variant in SCN1A causing SCN1A-Related Seizure Disorder phenotype (1.8e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.3521C>G has been reported in the literature but evidence does not allow for unequivocal conclusions regarding association of the variant with disease. Specifically, the variant was found to segregate with SCN1A-Related Seizure Disorder in some families (e.g. Cestele_2013, Lal_2016), while in other families it was found in affected probands who had inherited it from their unaffected parents or in families with some affected and some unaffected carriers (e.g. Yordanova_2011, LeGal_2014, Lal_2016, Till_2020). In addition, co-occurring pathogenic variants have been reported in multiple affected individuals (SCN1A c.3637C>T, p.Arg1213X; GRIN2B c.1619G>A, p.R540H; SCN1A c.4219C>T, p.Arg1407X; SCN1A c.3677delT, p.Phe1226SerfsX2) (Internal testing, Lal_2016, Till_2020), providing supporting evidence for a benign role. Functional effects were divergent: positive shift of the activation curve and deceleration of recovery from fast inactivation, consistent with loss of function, and increase of persistent current (INaP), consistent with gain of function (Cestele_2013). However, it is uncertain to what extent and if these findings correlate with actual disease manifestation. Twelve ClinVar submitters have assessed the variant since 2014: eight classified the variant as benign/likely benign, three as of uncertain significance and one as pathogenic. Based on the evidence outlined above, the variant was classified as benign. - |
Generalized epilepsy with febrile seizures plus, type 2 Benign:2
Benign, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Apr 26, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Severe myoclonic epilepsy in infancy Benign:1Other:1
not provided, no classification provided | literature only | Channelopathy-Associated Epilepsy Research Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | Mendelics | Aug 22, 2023 | - - |
Childhood epilepsy with centrotemporal spikes Pathogenic:1
Pathogenic, no assertion criteria provided | case-control | Bioinformatics Core, Luxembourg Center for Systems Biomedicine | Jan 01, 2017 | CAADphred>15 - |
Seizure;C0494475:Bilateral tonic-clonic seizure;C4316903:Generalized non-motor (absence) seizure Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Nov 13, 2014 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 17, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Early infantile epileptic encephalopathy with suppression bursts Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
SCN1A-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 29, 2021 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Epilepsy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at